Multiple Myeloma is a condition in which a group of plasma cells become cancerous and start to multiply, eventually destroying the body. This disease is most known to damage the bones, immune system, red blood cells and the kidneys. There are many medical treatments that could be used to slow down the outcomes of Multiple Myeloma, one of them being Bisphosphonates. Specifically talking about Pamidronate and Zoledronic Acid, both of which are common medications that are used to treat Multiple Myeloma, these medications are also known to cause kidney damage, leading to Acute Kidney Injury and Chronic Kidney Disease.
This study focuses on a group that was diagnosed with Multiple Myeloma and prescribed biphosphates at the time of diagnosis. It then follows these patients and measures their renal function over the course of six months. Results found that over 40% of the people that developed renal impairment were prescribed bisphosphonates, and about 80% of those that developed acute kidney injury at 6 months, later developed Chronic Kidney Disease within a year after the diagnosis of multiple myeloma. The study suggest that patients diagnosed with multiple myeloma should not be prescribed bisphosphonates due to their participation in the progression toward chronic kidney disease.
This entry is licensed under a Creative Commons CC0 1.0 Universal Public Domain Dedication license.
